Stocks Close Higher as Small-Caps, Techs Gain

NEW YORK (TheStreet) -- U.S. stocks gained Monday as small-cap and tech stocks surged against a backdrop of mixed M&A success. Talks between AstraZeneca (AZN) and Pfizer (PFE) appeared to have broken down and sentiment was cool over an AT&T (T) and DirecTV (DTV) merger agreement. Chinese authorities are also cracking down on the shadow-banking system in the world's second-largest economy, denting shares in Asia.



WATCH: More market update videos on TheStreet TV

A lackluster first-quarter earnings season is wrapping up in the U.S. With more than 90% of companies having posted results, profit gains among S&P 500 stocks are up just more than 2% from a year earlier, according to FactSet.

  • The Dow Jones Industrial Average added 0.15% to 16,516.46, while the S&P 500 was up 0.4% to 1,885.45. The Nasdaq jumped 0.88% to 4,126.40.
  • AT&T shares dropped 0.98% and DirecTV lost 1.8% after the two entered an agreement for AT&T to buy DirecTV for $48.5 billion.
  • AstraZeneca tumbled 12% after rejecting what Pfizer said would be its final offer for the British rival. AstraZeneca said the sweetened offer of 55 pounds ($95.52) a share undervalued the company. Pfizer was up 1.03%.
  • Campbell Soup (CPB) stumbled 2.4% lower after cutting sales guidance for fiscal 2014.
  • Internet stocks such as Netflix (NFLX), Google (GOOG) and Facebook (FB) increased, up 4.2%, 1.6% and 2.1%, respectively. Small-cap stocks as measured by the Russell 2000 popped 1%.
  • European markets were mixed. The DAX closed 0.31% higher and the FTSE lower by 0.16%. Asian markets were also weak, down on headlines that the Chinese government may tighten interbank lending to reduce the risks associated with the shadow banking system. The Hong Kong Hang Seng settled down 0.04% and the Nikkei 225 fell 0.64%. The Shanghai Composite declined 1.05%.
  • San Francisco Fed President John Williams said Monday that the central bank has been looking for ways to implement rate hikes and exit plans without causing disturbing inflation levels.
-- By Jane Searle, Andrea Tse and Joe Deaux in New York

>>Read More:

AstraZeneca Rejects 'Final' Pfizer Offer

Five Worst Airline Fees for Memorial Day Weekend

If you liked this article you might like

Profit With Technical Analysis: Cramer's 'Mad Money' Recap (Tuesday 2/20/18)

Profit With Technical Analysis: Cramer's 'Mad Money' Recap (Tuesday 2/20/18)

Jim Cramer: These 4 Stocks Seem Attractive Right Here

Jim Cramer: These 4 Stocks Seem Attractive Right Here

3 Reasons Pfizer May Want to Buy Bristol-Myers Squibb

3 Reasons Pfizer May Want to Buy Bristol-Myers Squibb

With the Correction In Pfizer Behind Us, Traders Can Go Long Again

With the Correction In Pfizer Behind Us, Traders Can Go Long Again

Axovant Shares Crater as CEO and President Both Resign

Axovant Shares Crater as CEO and President Both Resign